UBS Group Has Lowered Expectations for Pediatrix Medical Group (NYSE:MD) Stock Price

Pediatrix Medical Group (NYSE:MD - Free Report) had its price objective decreased by UBS Group from $18.50 to $16.00 in a research note released on Monday morning,Benzinga reports. UBS Group currently has a neutral rating on the stock.

Several other research firms also recently commented on MD. Macquarie upped their price objective on shares of Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. StockNews.com raised Pediatrix Medical Group from a "hold" rating to a "buy" rating in a research report on Wednesday, January 22nd. Finally, Truist Financial reduced their price objective on Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $16.67.

Pediatrix Medical Group Stock Performance

Shares of NYSE MD traded up $0.01 during mid-day trading on Monday, hitting $14.89. The stock had a trading volume of 785,750 shares, compared to its average volume of 853,113. The firm has a market cap of $1.28 billion, a PE ratio of -12.41, a PEG ratio of 1.74 and a beta of 1.26. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.42 and a current ratio of 1.60. The company has a 50 day moving average of $13.71 and a two-hundred day moving average of $14.10. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $17.67.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.08. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. The business had revenue of $458.36 million for the quarter, compared to analyst estimates of $451.44 million. During the same period in the prior year, the company earned $0.20 earnings per share. The company's revenue was down 7.4% on a year-over-year basis. Research analysts predict that Pediatrix Medical Group will post 1.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Pediatrix Medical Group

Several hedge funds have recently modified their holdings of MD. Franklin Resources Inc. acquired a new position in Pediatrix Medical Group in the 3rd quarter worth about $598,000. Harbor Capital Advisors Inc. raised its stake in shares of Pediatrix Medical Group by 11.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 53,717 shares of the company's stock worth $705,000 after buying an additional 5,712 shares during the period. Ritholtz Wealth Management purchased a new position in shares of Pediatrix Medical Group during the 4th quarter valued at approximately $182,000. SG Americas Securities LLC acquired a new stake in Pediatrix Medical Group in the 4th quarter valued at $171,000. Finally, Pacer Advisors Inc. purchased a new stake in Pediatrix Medical Group in the 4th quarter worth $35,492,000. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.